Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 3
2013 2
2014 1
2015 3
2016 4
2017 5
2018 2
2019 4
2020 3
2021 5
2022 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
New Immuno-oncology Targets and Resistance Mechanisms.
Tokaz MC, Baik CS, Houghton AM, Tseng D. Tokaz MC, et al. Among authors: baik cs. Curr Treat Options Oncol. 2022 Sep;23(9):1201-1218. doi: 10.1007/s11864-022-01005-8. Epub 2022 Aug 18. Curr Treat Options Oncol. 2022. PMID: 35980521 Review.
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC.
Johnson BE, Baik CS, Mazieres J, Groen HJM, Melosky B, Wolf J, Zadeh Vosta Kolaei FA, Wu WH, Knoll S, Ktiouet Dawson M, Johns A, Planchard D. Johnson BE, et al. Among authors: baik cs. JTO Clin Res Rep. 2022 Apr 6;3(5):100324. doi: 10.1016/j.jtocrr.2022.100324. eCollection 2022 May. JTO Clin Res Rep. 2022. PMID: 35592617 Free PMC article.
Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.
Bowen SR, Hippe DS, Thomas HM, Sasidharan B, Lampe PD, Baik CS, Eaton KD, Lee S, Martins RG, Santana-Davila R, Chen DL, Kinahan PE, Miyaoka RS, Vesselle HJ, Houghton AM, Rengan R, Zeng J. Bowen SR, et al. Among authors: baik cs. Adv Radiat Oncol. 2021 Nov 21;7(2):100857. doi: 10.1016/j.adro.2021.100857. eCollection 2022 Mar-Apr. Adv Radiat Oncol. 2021. PMID: 35387421 Free PMC article.
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Among authors: baik cs. Cancer Med. 2022 Nov;11(22):4104-4111. doi: 10.1002/cam4.4722. Epub 2022 Mar 29. Cancer Med. 2022. PMID: 35349227 Free PMC article.
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
Chalker C, Santana-Davila R, Voutsinas JM, Wu QV, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Among authors: baik cs. J Palliat Med. 2022 Apr;25(4):614-619. doi: 10.1089/jpm.2021.0323. Epub 2021 Nov 30. J Palliat Med. 2022. PMID: 34847733
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Subbiah V, et al. Among authors: baik cs. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Lancet Diabetes Endocrinol. 2021. PMID: 34118198 Clinical Trial.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Gainor JF, et al. Among authors: baik cs. Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9. Lancet Oncol. 2021. PMID: 34118197 Clinical Trial.
33 results